|
|
Atazanavir Labeling Changes
Click here to view original press release.
Accession Number
A00758
Author
U.S. Food and Drug Administration
Source
FDA List Serv Announcement
Release Date
November 27, 2006
Major Descriptors
Atazanavir
Topic
Drugs and Treatment
Text
The following text was added to this section.
Atazanavir is a metabolism-dependent CYP3A inhibitor, with a Kinact value of 0.05 to 0.06 min-1 and Ki value of 0.84 to 1.0 ìM. Atazanavir is also a direct inhibitor for UGT1A1 (Ki =1.9 ìM) and CYP2C8 (Ki =2.1 ìM). REYATAZ should not be administered concurrently with medications with narrow therapeutic windows that are substrates of CYP3A, UGT1A1, or CYP2C8 (see CONTRAINDICATIONS).
Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2, or CYP2E1.
The following information was added to Table 4: Drug Interactions: Pharmacokinetic Parameters for Atazanavir in the Presence of Coadministered Drugs
PRECAUTIONS: Drug Interactions
Information regarding atazanavir is an inhibitor of CYP2C8 was added. In addition the following text was added.
Reduced plasma concentrations of atazanavir are expected if proton-pump inhibitors (see Table 10), antacids, buffered medications, or H2-receptor antagonists (see Table 11) are administered with atazanavir.
The following text was added or revised in Table 10 and 11:
Table 10 Drugs That Should Not Be Administered with Reyataz
Antimycobacterials: rifampin Rifampin substantially decreases plasma concentrations of atazanavir, which may result in loss of therapeutic effect and development of resistance.
Proton-Pump Inhibitors Omeprazole substantially decreases plasma concentrations of atazanavir. Concomitant use of proton-pump inhibitors and REYATAZ may result in loss of therapeutic effect and development of resistance.
Table 11: Established and Other Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies a or Predicted Interactions
(Information in the table applies to REYATAZ with or without ritonavir, unless otherwise indicated):
atazanavir
didanosine
Coadministration of REYATAZ with didanosine buffered tablets results in a marked decrease in atazanavir exposure. It is recommended that REYATAZ be given (with food) 2 h before or 1 hr after didanosine buffered formulations. Simultaneous administration of didanosine EC and REYATAZ with food results in a decrease in didanosine exposure. Thus, REYATAZ and didanosine EC should be administered at different times.
Antifungals:
voriconazole
Effect is unknown
Coadministration of voriconazole with REYATAZ, with or without ritonavir, has not been studied. Administration of voriconazole with ritonavir 100 mg every 12 hours decreased voriconazole steady-state AUC by an average of 39%. Voriconazole should not be administered to patients receiving REYATAZ/ritonavir, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole. Coadministration of voriconazole with REYATAZ (without ritonavir) may increase atazanavir concentrations; however, no data are available.
H2-Receptor
antagonists
atazanavir
Plasma concentrations of atazanavir were substantially decreased when REYATAZ 400 mg once daily was administered simultaneously with famotidine 40 mg twice daily, which may result in loss of therapeutic effect and development of resistance.
In treatment-naive patients taking an H2-receptor antagonist, either of the following regimens may be used: REYATAZ 400 mg once daily with food at least 2 hours before and at least 10 hours after the H2-receptor antagonist OR REYATAZ 300 mg with ritonavir 100 mg once daily with food, without the need for separation from the H2-receptor antagonist. In treatment-experienced patients, the following regimen should be used: REYATAZ 300 mg with ritonavir 100 mg once daily with food at least 2 hours before and at least 10 hours after the H2-receptor antagonist.
Additionally, the following text was added to the drug interaction secion:
No clinically significant drug interaction was observed when REYATAZ was coadministered with methadone.
DOSAGE AND ADMINISTRATION
The following text was included in this section:
Didanosine. When coadministered with didanosine buffered or enteric-coated formulations, REYATAZ should be given (with food) 2 hours before or 1 hour after didanosine.
H2-receptor antagonists.
Treatment-naïve patients: REYATAZ 400 mg once daily with food at least 2 hours before and at least 10 hours after the H2-receptor antagonist OR REYATAZ 300 mg with ritonavir 100 mg once daily with food, without the need for separation from the H2-receptor antagonist.
Treatment-experienced patients: REYATAZ 300 mg with ritonavir 100 mg once daily with food at least 2 hours before and at least 10 hours after the H2-receptor antagonist.
Richard Klein Office of Special Health Issues Food and Drug Administration
Kimberly Struble Division of Antiviral Drug Products Food and Drug Administration
An archive of past list serve announcements is available on the FDA web site at http://www.fda.gov/oashi/aids/listserve/archive.html
This release was provided by the FDA and p
|